Brian Van Tine | Oncology | Saint Louis, MO

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Enrollment Status: Recruiting

Publish Date: January 13, 2025

Intervention Type: Drug

Study Drug: INBRX-109

Study Phase: Phase 2

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: February 24, 2025

Intervention Type: Procedure, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: February 14, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel

Study Phase: Phase 2

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Procedure, Drug

Study Drug: Rogaratinib

Study Phase: Phase 2

A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: February 03, 2025

Intervention Type: Drug

Study Drugs: Cabozantinib, Nivolumab, Ipilimumab

Study Phase: Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Enrollment Status: Completed

Publish Date: January 31, 2025

Intervention Type: Drug

Study Drug: Nirogacestat Oral Tablet

Study Phase: Phase 3

A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Efatutazone

Study Phase: Phase 2

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Enrollment Status: Active_not_recruiting

Publish Date: January 23, 2025

Intervention Type: Drug

Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine

Study Phase: Phase 1/Phase 2

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Genetic

Study Phase: Phase 2

A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Enrollment Status: Active_not_recruiting

Publish Date: December 31, 2024

Intervention Type: Other, Drug

Study Drugs: Cabozantinib, Temozolomide

Study Phase: Phase 2

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: December 27, 2024

Intervention Type: Procedure, Biological, Drug

Study Drugs: Atezolizumab, Bevacizumab

Study Phase: Phase 2

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: December 18, 2024

Intervention Type: Procedure, Drug

Study Phase: Phase 2

A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2024

Intervention Type: Drug, Radiation, Procedure

Study Drug: MDM2 Inhibitor KRT-232

Study Phase: Phase 1

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

Enrollment Status: Completed

Publish Date: November 26, 2024

Intervention Type: Other, Drug

Study Drug: Trametinib

Study Phase: Phase 2

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors

Enrollment Status: Terminated

Publish Date: November 26, 2024

Intervention Type: Drug

Study Drugs: GSK3901961, GSK3845097, Fludarabine, Cyclophosphamide

Study Phase: Phase 1

Phase 1B/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects with Previously Treated Soft-Tissue Sarcomas with Pulmonary Metastases

Enrollment Status: Completed

Publish Date: October 24, 2024

Intervention Type: Drug

Study Drug: Liposomal Annamycin

Study Phase: Phase 1/Phase 2

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity

Enrollment Status: Active_not_recruiting

Publish Date: October 17, 2024

Intervention Type: Drug

Study Drug: Mirdametinib

Study Phase: Phase 2

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2024

Intervention Type: Drug

Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide

Study Phase: Phase 2

A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers

Enrollment Status: Terminated

Publish Date: September 04, 2024

Intervention Type: Genetic

Study Phase: Phase 2

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Enrollment Status: Completed

Publish Date: August 29, 2024

Intervention Type: Radiation, Procedure

Study Phase: Not Applicable

PROactive Evaluation of Function to Avoid CardioToxicity

Enrollment Status: Terminated

Publish Date: July 17, 2024

Intervention Type: Device

Study Phase: Phase 2

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Enrollment Status: Completed

Publish Date: July 01, 2024

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma

Enrollment Status: Completed

Publish Date: March 15, 2024

Intervention Type: Drug

Study Drugs: PTC596, Dacarbazine

Study Phase: Phase 1

Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors

Enrollment Status: Active_not_recruiting

Publish Date: March 13, 2024

Intervention Type: Drug

Study Drugs: PLX3397, Sirolimus

Study Phase: Phase 1/Phase 2

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: January 31, 2024

Intervention Type: Drug

Study Drugs: Anlotinib, Decarbazine

Study Phase: Phase 3

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2024

Intervention Type: Genetic, Radiation

Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells

Study Phase: Phase 1

Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Enrollment Status: Active_not_recruiting

Publish Date: November 21, 2023

Intervention Type: Drug

Study Drugs: Seclidemstat, Cyclophosphamide, Topotecan

Study Phase: Phase 1

A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Enrollment Status: Completed

Publish Date: November 07, 2023

Intervention Type: Drug

Study Drugs: Dexrazoxane, Doxorubicin

Study Phase: Phase 2

Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

Enrollment Status: Completed

Publish Date: October 17, 2023

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma

Enrollment Status: Terminated

Publish Date: September 13, 2023

Intervention Type: Drug

Study Drugs: Ramucirumab, Gemcitabine, Docetaxel

Study Phase: Phase 1/Phase 2

A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: September 08, 2023

Intervention Type: Drug, Procedure

Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel

Study Phase: Phase 2

A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma

Enrollment Status: Completed

Publish Date: April 11, 2023

Intervention Type: Drug

Study Drugs: Letetresgene autoleucel, Cyclophosphamide, Fludarabine

Study Phase: Phase 2

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Enrollment Status: Completed

Publish Date: January 23, 2023

Intervention Type: Drug

Study Drug: Selinexor

Study Phase: Phase 2/Phase 3

A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.

Enrollment Status: Completed

Publish Date: December 22, 2022

Intervention Type: Drug, Biological

Study Phase: Phase 2

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Enrollment Status: Completed

Publish Date: October 06, 2022

Intervention Type: Drug

Study Drugs: Avapritinib, Regorafenib

Study Phase: Phase 3

A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Enrollment Status: Terminated

Publish Date: August 23, 2022

Intervention Type: Drug

Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib

Study Phase: Phase 1/Phase 2

A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

Enrollment Status: Completed

Publish Date: June 07, 2022

Intervention Type: Drug, Other

Study Drugs: Pazopanib Hydrochloride, Topotecan Hydrochloride

Study Phase: Phase 2

A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

Enrollment Status: Completed

Publish Date: May 09, 2022

Intervention Type: Drug

Study Drugs: Olaratumab, Gemcitabine, Docetaxel

Study Phase: Phase 1/Phase 2

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Enrollment Status: Completed

Publish Date: April 25, 2022

Intervention Type: Drug

Study Drug: Regorafenib

Study Phase: Phase 2

Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery

Enrollment Status: Terminated

Publish Date: April 12, 2022

Intervention Type: Other

Study Phase: Not Applicable

A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Enrollment Status: Terminated

Publish Date: March 11, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Enrollment Status: Withdrawn

Publish Date: December 23, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

Enrollment Status: Completed

Publish Date: November 22, 2021

Intervention Type: Radiation, Procedure

Study Phase: Not Applicable

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

Enrollment Status: Unknown

Publish Date: October 26, 2021

Intervention Type: Drug

Study Drug: Enzalutamide

Study Phase: Phase 2

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Enrollment Status: Completed

Publish Date: June 30, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase I Trial of Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

Enrollment Status: Withdrawn

Publish Date: September 16, 2020

Intervention Type: Radiation

Study Phase: Not Applicable

A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Enrollment Status: Completed

Publish Date: August 05, 2020

Intervention Type: Drug

Study Phase: Phase 2

A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Enrollment Status: Terminated

Publish Date: July 07, 2020

Intervention Type: Biological

Study Phase: Phase 2

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)

Enrollment Status: Terminated

Publish Date: April 16, 2020

Intervention Type: Biological, Other

Study Phase: Phase 3

A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Enrollment Status: Completed

Publish Date: April 06, 2020

Intervention Type: Drug

Study Phase: Phase 2

Dr. Brian Van Tine

Overview

Insurance

Locations

Additional Areas of Focus

Clinical Research

53 Clinical Trials

152 Total Publications

Washington University

Washington University

Areas of Expertise